To the full analysis
Buyback calculator for Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals stock: key metrics
ARWRArrowhead Pharmaceuticals had an operating margin of −156.9% and a return on invested capital (ROIC) of −42% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | −874.8% | −3,141.4% | −2,477.7% |
| 2008 | −1,039.8% | −2,685.9% | −2,078.7% |
| 2009 | −139.9% | −520.5% | −513.8% |
| 2010 | −698.7% | −1,419.5% | −931.2% |
| 2011 | 9.5% | −3,319.5% | −1,056.6% |
| 2012 | −1,090.8% | −14,358.6% | −14,383.6% |
| 2013 | −993.2% | −8,471.3% | −10,729.2% |
| 2014 | −2,076.2% | −30,443.6% | −33,503.0% |
| 2015 | 0.0% | −25,124.1% | −24,068.3% |
| 2016 | 0.0% | −51,627.1% | −51,614.6% |
| 2017 | 0.0% | −117.8% | −109.5% |
| 2018 | 0.0% | −346.5% | −337.3% |
| 2019 | 0.0% | 36.3% | 40.3% |
| 2020 | 0.0% | −105.9% | −96.1% |
| 2021 | 100.0% | −107.8% | −101.9% |
| 2022 | 95.7% | −73.4% | −72.4% |
| 2023 | 94.8% | −85.2% | −85.3% |
| 2024 | −423.7% | −16,927.1% | −16,882.4% |
| 2025 | 100.0% | 11.9% | −0.2% |
| 2026 | 99.6% | −156.9% | −160.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | −100.0% | no data | −100.0% |
| 2008 | −100.0% | no data | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | −63.8% | −94.8% | −46.7% |
| 2011 | −22.9% | −71.0% | −19.7% |
| 2012 | −100.0% | no data | −100.0% |
| 2013 | −100.0% | −94.3% | −83.4% |
| 2014 | −35.2% | −41.9% | −32.1% |
| 2015 | −83.4% | −52.7% | −69.5% |
| 2016 | −85.5% | −58.9% | −63.8% |
| 2017 | −42.2% | −31.0% | −33.1% |
| 2018 | −56.8% | −47.8% | −48.8% |
| 2019 | 27.8% | 34.7% | 19.4% |
| 2020 | −18.3% | −96.4% | −16.2% |
| 2021 | −34.5% | −22.5% | −19.8% |
| 2022 | −44.2% | −25.1% | −25.4% |
| 2023 | −75.7% | −82.9% | −26.8% |
| 2024 | −100.0% | −55.4% | −52.6% |
| 2025 | −0.3% | 36.8% | −0.1% |
| 2026 | −100.0% | −42.0% | −41.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 May 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.